The antiviral for COVID-19 added $952m to Merck's top line in 2021 and is forecast to deliver $5bn-$6bn in 2022, but CEO Davis sees potential for the product beyond the current pandemic, including potential combinations.
Merck & Co., Inc.'s strong fourth quarter sales were helped by $952m in revenue from the antiviral molnupiravir for COVID-19 at the end of the year, and while the product is expected to be a blockbuster-sized contributor to financials in 2022, CEO Robert Davis said there could be a longer-term commercial opportunity for the product as well.
"We do see potential for molnupiravir beyond the current situation with COVID-19 and the pandemic, given the fact that it...
Merck’s immuno-oncology blockbuster was the world’s best-selling drugs by revenues for the second year in a row, with an almost $12bn lead over its closest rival, Novo Nordisk’s GLP-1 drug Ozempic.
Nancy tests Jira ticket SPARC-1036: Make anchor link work on initial page load
2030 sales forecasts for Novo’s obesity hope are an order of magnitude larger than its closest rival among 2025’s expected debutantes.
Tarsus Pharmaceuticals is putting more sales and marketing heft behind its novel eyelid disease therapy, Xdemvy, to capitalize on a solid start in a previously untapped market.
Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.
Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.
A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.
